You started semaglutide expecting things to move. And for the first few weeks, maybe they did: appetite down, portions smaller, the scale dropping. Then it stopped. Or maybe nothing ever happened at all.
This is one of the most common questions providers hear from patients on GLP-1 medications, and there is rarely a single, simple answer. Semaglutide works differently in different bodies, and "working" doesn't always look the same week to week. But there are specific, addressable reasons why weight loss can stall or fail to start, and knowing which one applies to you changes what to do next.
Semaglutide is a titrated medication. You don't start at a therapeutic dose. You start at the lowest dose possible to minimize nausea and other GI side effects, and then increase gradually over weeks or months until you reach a dose that produces meaningful appetite suppression.
Most people don't experience significant weight loss at the 0.25 mg or 0.5 mg starting doses. These are tolerance-building steps, not treatment doses. The meaningful weight loss in the clinical trials (the 10 to 15 percent reduction in body weight seen over 68 weeks) happened at the 2.4 mg weekly dose (for Wegovy) or equivalent high-range doses in compound form.
If you've been on semaglutide for six to eight weeks but haven't titrated up yet, you may simply not be at the dose that changes your appetite in a significant way. Talk to your provider about your titration schedule.
Semaglutide is not a rapid-acting medication. The phase 3 clinical trials measured results over 16 months, not 6 weeks. Most patients in those trials saw the bulk of their weight loss occur between weeks 8 and 52, with earlier weeks showing smaller, slower changes.
A common pattern is modest initial loss (partly water weight, partly from reduced intake), followed by a slower-looking middle period where fat loss is happening but the scale isn't moving dramatically. If you're three to four weeks in and frustrated, you're likely still in the adjustment window.
That said, "give it more time" is not a blank check. If you've been at a stable therapeutic dose for three months with minimal results, something specific is getting in the way.
Semaglutide suppresses appetite, but it doesn't control what you choose to eat or how much you consume at the moments when it matters. A documented pattern in GLP-1 patients is caloric compensation: appetite drops during the day, so meals get smaller, but later in the evening or on weekends, eating patterns drift back up. Liquid calories (alcohol, juice, sweetened coffee drinks) often go untracked entirely.
This doesn't mean semaglutide isn't working. It means appetite suppression alone doesn't automatically produce weight loss unless caloric intake actually decreases below what your body burns. Tracking food for even two weeks can be clarifying, not as a permanent practice, but as a diagnostic one.
Semaglutide reduces calorie intake. When calorie intake drops sharply without adequate protein or resistance exercise, the body loses both fat and muscle tissue. Muscle is metabolically active. Losing it lowers your resting metabolic rate, meaning your body burns fewer calories at rest. Over time, this can slow or halt weight loss even if you're eating less than before.
Research on GLP-1 medications and body composition shows that patients who don't exercise while on semaglutide can lose a disproportionate amount of lean mass relative to fat. The number on the scale may not reflect this. You might weigh less but have worse body composition than when you started.
The fix is straightforward: eat enough protein (most guidelines for GLP-1 patients recommend at least 1.2 grams per kilogram of body weight daily) and include resistance training two to three times per week. This preserves muscle while fat loss continues.
Several medical conditions make weight loss significantly harder, even with medication. The ones most commonly overlooked include:
Hypothyroidism. An underactive thyroid slows metabolism. Many people with mild or subclinical hypothyroidism don't have obvious symptoms, and standard annual panels don't always catch it. A TSH and free T4 test can rule this out.
Insulin resistance and type 2 diabetes. Semaglutide was originally developed as a diabetes medication and does improve insulin sensitivity. But in people with significant insulin resistance, weight loss tends to be slower because chronically elevated insulin encourages fat storage. Managing carbohydrate intake alongside medication often accelerates results in this group.
Sleep apnea. Disrupted sleep raises cortisol and ghrelin (the hunger hormone) while suppressing leptin (the satiety hormone). Even with a medication that reduces appetite, poor sleep quality works against it. Untreated sleep apnea is one of the most underrecognized barriers to weight loss.
PCOS. Women with polycystic ovary syndrome have hormonal profiles that make weight loss harder. Semaglutide does help, but results can be slower than average and often require addressing the hormonal picture alongside the medication.
If you haven't had labs done recently, it's worth asking your provider about a metabolic panel that includes thyroid function.
Several commonly prescribed medications promote weight gain or counteract the appetite-suppressing effects of GLP-1s. Antidepressants (particularly mirtazapine, paroxetine, and some tricyclics), antipsychotics, corticosteroids, certain blood pressure medications (like beta-blockers), and some antihistamines taken regularly can all work against weight loss.
This doesn't necessarily mean you need to stop those medications. Often there are alternatives within the same class that are more weight-neutral. A conversation with your prescribing provider about the full list of medications you're on is worth having.
If you've been at a stable therapeutic dose of semaglutide for 12 weeks or longer and have lost less than 5 percent of your starting body weight, that's a meaningful signal that something needs to change. It might be the dose, the titration speed, a concurrent medication, an underlying condition, or a shift to a different GLP-1 medication entirely (tirzepatide, for instance, shows stronger average weight loss in head-to-head comparisons).
The goal isn't to push through indefinitely on a protocol that isn't working. Semaglutide is a tool, and like any tool, it works best when it's matched to the right situation. If it isn't producing results after a fair trial, that's information, and your provider can help you act on it.
Pomegranate offers physician-guided semaglutide programs with ongoing provider support. If you have questions about your current dose or aren't seeing the results you expected, your care team is available to help.
Get quick answers to the most common questions about our platform and services.
We’re currently experiencing higher than usual volume. Expect to hear from us within
5–7 business days.
We look forward to taking great care of you.
